La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Tonix Pharmaceuticals Holding Crescita futura

Future criteri di controllo 2/6

Si prevede che Tonix Pharmaceuticals Holding aumenterà gli utili e i ricavi rispettivamente del 32.8% e 51.1% all'anno, mentre si prevede che l'EPS crescerà del 99.4% all'anno.

Informazioni chiave

33.8%

Tasso di crescita degli utili

128.0%

Tasso di crescita dell'EPS

Biotechs crescita degli utili	28.5%
Tasso di crescita dei ricavi	51.5%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Low
Ultimo aggiornamento	09 Sep 2024

Aggiornamenti recenti sulla crescita futura

Nessun aggiornamento

Recent updates

Previsioni di crescita degli utili e dei ricavi

NasdaqCM:TNXP - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	41	-63	N/A	N/A	2
12/31/2025	16	-76	N/A	N/A	3
12/31/2024	9	-80	N/A	N/A	1
6/30/2024	12	-149	-76	-73	N/A
3/31/2024	10	-99	-91	-87	N/A
12/31/2023	8	-117	-110	-102	N/A
9/30/2023	4	-123	-114	-102	N/A
6/30/2023	N/A	-124	-121	-102	N/A
3/31/2023	N/A	-123	-132	-100	N/A
12/31/2022	N/A	-117	-146	-98	N/A
9/30/2022	N/A	-112	-167	-98	N/A
6/30/2022	N/A	-102	-156	-88	N/A
3/31/2022	N/A	-98	-141	-86	N/A
12/31/2021	N/A	-92	-111	-76	N/A
9/30/2021	N/A	-80	-81	-67	N/A
6/30/2021	N/A	-73	-80	-69	N/A
3/31/2021	N/A	-64	-69	-60	N/A
12/31/2020	N/A	-52	-57	-49	N/A
9/30/2020	N/A	-46	-45	-41	N/A
6/30/2020	N/A	-42	-33	-33	N/A
3/31/2020	N/A	-34	-27	-27	N/A
12/31/2019	N/A	-31	-27	-27	N/A
9/30/2019	N/A	-31	-27	-27	N/A
6/30/2019	N/A	-28	-25	-25	N/A
3/31/2019	N/A	-29	-26	-26	N/A
12/31/2018	N/A	-29	-24	-24	N/A
9/30/2018	N/A	-24	-22	-22	N/A
6/30/2018	N/A	-24	-22	-22	N/A
3/31/2018	N/A	-23	N/A	-21	N/A
12/31/2017	N/A	-21	N/A	-19	N/A
9/30/2017	N/A	-23	N/A	-20	N/A
6/30/2017	N/A	-25	N/A	-23	N/A
3/31/2017	N/A	-30	N/A	-27	N/A
12/31/2016	N/A	-39	N/A	-37	N/A
9/30/2016	N/A	-45	N/A	-44	N/A
6/30/2016	N/A	-50	N/A	-48	N/A
3/31/2016	N/A	-52	N/A	-49	N/A
12/31/2015	N/A	-48	N/A	-43	N/A
9/30/2015	N/A	-44	N/A	-39	N/A
6/30/2015	N/A	-38	N/A	-31	N/A
3/31/2015	N/A	-32	N/A	-28	N/A
12/31/2014	N/A	-28	N/A	-23	N/A
9/30/2014	N/A	-22	N/A	-18	N/A
6/30/2014	N/A	-18	N/A	-16	N/A
3/31/2014	N/A	-14	N/A	-11	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che TNXP rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che TNXP rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che TNXP rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di TNXP ( 51.1% all'anno) crescerà più rapidamente del mercato US ( 8.8% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di TNXP ( 51.1% all'anno) crescerà più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di TNXP è previsto essere elevato tra 3 anni

Tonix Pharmaceuticals Holding Crescita futura

Future criteri di controllo 2/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Recent updates

Tonix Pharmaceuticals Holding Corp. Announces its Single Dose Mpox Vaccine Candidate TNX-801 Aligns with WHO's Newly Issued Preferred Target Product Profile for Mpox Vaccines in Global Health Emergency

Tonix Pharmaceuticals Presents Data on the Potential Mpox Vaccine TNX-801 in Using Synthetic Biology to Battle Mpox Vaccine

Tonix Pharmaceuticals Holding Corp Announces the Appointment of Thomas Englese as Executive Vice President of Commercial Operations

Tonix Pharmaceuticals Holding Corp. (NasdaqCM:TNXP) announces an Equity Buyback for $10 million worth of its shares.

Tonix Pharmaceuticals Holding Corp. Presents Data from Two Posters on TNX-102 SL for Reduction of Acute Stress Reaction and Prevention of PTSD and One Poster for Wound Healing at the 2024 Military Health System Research Symposium

Tonix Pharmaceuticals Holding Corp. Presents Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the 2024 Military Health System Research Symposium

Tonix Pharmaceuticals Holding Corp. Announces First Patient Enrolled in Phase 2 CATALYST Study of TNX-1300 for the Treatment of Cocaine Intoxication

Tonix Pharmaceuticals Holding Corp. Provides Update on the Development of Its Single Dose Live Attenuated Virus Vaccine Candidate for Mpox, Tnx-801, as Who Declares Mpox Outbreak A Global Health Emergency

Tonix Pharmaceuticals Holding Corp. Presents Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia, the Prototypic Nociplastic Pain Syndrome, at the IASP 2024 World Congress on Pain

Tonix Pharmaceuticals Holding Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

Tonix Pharmaceuticals Holding Corp. Announces Potential Positive Impact of U.S. National Academies New Definition of Long COVID on Size of Fibromyalgia Market for Tonmya

Tonix Pharmaceuticals Holding Corp. has filed a Follow-on Equity Offering in the amount of $50 million.

Tonix Pharmaceuticals Holding Corp. Grants Fast Track Designation by FDA for Tonmya for Fibromyalgia

Tonix Pharmaceuticals Holding Corp. Set to File an NDA for Tonmya for the Management of Fibromyalgia, Is Planning Expected Launch in 2H 2025

Tonix Pharmaceuticals Holding Corp. announced that it expects to receive $30 million in funding

Tonix Pharmaceuticals Holding Corp. has filed a Follow-on Equity Offering.

Tonix Pharmaceuticals Reports Final Positive Pre-NDA Meeting with FDA for Tonmya™ for the Management of Fibromyalgia

Tonix Pharmaceuticals Holding Corp. has filed a Follow-on Equity Offering.

Tonix Pharmaceuticals Holding Corp. Presents Vaccine Platform Data in Keynote Talk At the Vaccine Congress 2024

Tonix Pharmaceuticals Holding Corp. Announces Positive Pre-NDA CMC Meeting with FDA for Tonmya for the Management of Fibromyalgia

Tonix Pharmaceuticals Holding Corp. has completed a Follow-on Equity Offering in the amount of $4.009881 million.

Tonix Pharmaceuticals Holding Corp. has filed a Follow-on Equity Offering.

Tonix Pharmaceuticals Holding Corp. Announces Two Oral Presentations and One Poster Presentation Involving TNX-1500

ToniTonix Pharmaceuticals Holding Corp. Presents New Data on Tonmya Suggesting Activity for Improvement in Fibromyalgia-Associated Depression Severity in an Oral Presentation at ASCP Annual Meeting

Tonix Pharmaceuticals Holding Corp., Annual General Meeting, May 02, 2024

Tonix Pharmaceuticals Holding Corp. has filed a Follow-on Equity Offering in the amount of $4.4 million.

Tonix Pharmaceuticals Announces Poster Presentation Describing Discovery of Novel Next-Generation Oxytocin Analogues At the American Chemistry Society (Acs) Spring 2024 Meeting

Tonix Pharmaceuticals Holding Corp. Announces Publication in Psychiatry Research Showing Activity of Bedtime TNX-102 SL on PTSD Symptoms and Sleep Quality in Military-Related PTSD at Four Weeks of Therapy

Tonix Pharmaceuticals Announces Translation of Preclinical Pharmacokinetic Parameters of TNX-1500 (Fc-modified humanized anti-CD40L mAb) Supports Monthly i.v. Dosing in Humans

Tonix Pharmaceuticals Completes Clinical Stage of Phase 1 Trial for TNX-1500 (Fc-Modified Humanized Anti-CD40L mAb) in Healthy Volunteers

Tonix Pharmaceuticals Reports Positive Phase 3 Study Results for Its Non-Opioid Painkiller in Late December

Tonix Pharmaceuticals Hosted KOL Webinar on Positive Phase 3 Fibromyalgia Trial for Tonmya™, Plans to File NDA for FDA Approval in Second Half of 2024

Tonix Pharmaceuticals Holding Corp. Announces FDA IND Clearance for DoD Funded Trial of TNX-102 SL for the Reduction of Acute Stress Response and Prevention of PTSD

Tonix Pharmaceuticals Presents Additional Data Highlighting the Favorable Tolerability and Differentiated Side Effect Profile of Tnx-102 Sl in Second Positive Phase 3 Clinical Trial for the Management of Fibromyalgia

Tonix Pharmaceuticals Holding Corp. has filed a Follow-on Equity Offering.

Tonix Pharmaceuticals Holding Corp. Announces Highly Statistically Significant and Clinically Meaningful Topline Results in Second Positive Phase 3 Clinical Trial of TNX-102 SL for the Management of Fibromyalgia

Tonix Pharmaceuticals Holding Corp. Announces IND Clearance by the FDA for Phase 2 Trial of TNX-2900 for the Treatment of Prader-Willi Syndrome, the Most Common Genetic Cause of Life-Threatening Childhood Obesity

Tonix Pharmaceuticals Holding Corp. Announces Enrollment Initiated in Mass General Brigham Phase 2 Investigator-Initiated Study of TNX-1900 (Intranasal Potentiated Oxytocin) for Bone Health in Children with Autism Spectrum Disorder

National Institute of Allergy and Infectious Diseases Selects Tonix Pharmaceuticals' Vaccine Candidate, TNX-1800, Selected by NIH/NIAID Project NextGen for Inclusion in Clinical Trials

Tonix Pharmaceuticals Holding Corp. Announces Topline Results from Phase 2 Proof-of-Concept Study of TNX-601 ER for the Treatment of Major Depressive Disorder

Tonix Pharmaceuticals Holding Corp. Completes Clinical Stage of Phase 2 PREVENTION Study of TNX-1900 for the Prevention of Migraine Headaches in Chronic Migraineurs

Tonix Pharmaceuticals Holding Corp. Receives a Letter from the Listing Qualifications Staff of the Nasdaq Stock Market

Tonix Pharmaceuticals Announces Publication of Data in the Journal Nature Involving Tnx-1500 (Fc-Modified Dimeric Anti-Cd40l Mab) for the Prevention of Rejection in Kidney Xenotransplantation in Animal Models

Tonix Pharmaceuticals Completes Clinical Stage of Phase 2 UPLIFT Study of TNX-601 ER for the Treatment of Major Depressive Disorder

Tonix Pharmaceuticals Announces Department of Defense Grant to Support the University of North Carolina’s Proposed Investigator Sponsored OASIS Trial of TNX-102 SL for Treatment of Acute Stress Reaction, Acute Stress Disorder, and Posttraumatic Stress Disorder

Tonix Pharmaceuticals Holding Corp. Announces Poster Presentation Showing Research Results for mTNX-1700

Tonix Pharmaceuticals Holding Corp. Announces Commitment to Supply Tosymra®? (Sumatriptan Nasal Spray) 10 Mg for Treatment of Acute Migraine

Tonix Pharmaceuticals Holding Corp. Announces Topline Results from Phase 2 Prevail Proof-Of-Concept Study of TNX-102 SL for the Management of Fibromyalgia-Type Long COVID

Tonix Pharmaceuticals Holding Corp. Announces Results of Pre-Ind Meeting with FDA for TNX-801 as A Potential Vaccine to Protect Against Mpox and Smallpox

Tonix Pharmaceuticals Initiates Phase 1 Trial of TNX-1500 (Fc-Modified Humanized Anti-Cd40l Mab) in Healthy Volunteers

Tonix Pharmaceuticals Completes Enrollment in Potentially NDA-Enabling Phase 3 RESILIENT Trial of TNX-102 SL for Management of Fibromyalgia

Tonix Pharmaceuticals Announces Enrollment Initiated in the MGH Phase 2 ‘STROBE’ Study of TNX-1900 (Intranasal Potentiated Oxytocin) for the Treatment of Binge-Eating Disorder

Tonix Pharmaceuticals Holding Corp. Announces Accelerating Completion of Enrollment in Phase 2 UPLIFT Study of TNX-601 ER (Racemic Tianeptine) for Major Depressive Disorder: Topline Data Now Expected in Fourth Quarter 2023

Tonix Pharmaceuticals Holding Corp. Announces Data Supporting Memory- and Cognition-Enhancing Effects of Racemic Tianeptine and (S)-Tianeptine, But Not (R)-Tianeptine, in Vivo Rat Novel Object Recognition Test

Tonix Pharmaceuticals Announces Initiation of Enrollment in the MGH Phase 2 ‘Power’ Study of TNX-1900 Intranasal Potentiated Oxytocin for the Treatment of Pediatric Obesity

Tonix Pharmaceuticals Holding Corp. (NasdaqCM:TNXP) and Tonix Medicines, Inc. entered into an agreement to acquire Certain Assets of Upsher Smith Laboratories, LLC for $25 million.

Tonix Pharmaceuticals Holding Corp. Announces Publication of Results from Phase 3 RELIEF Trial of TNX 102 SL for the Management of Fibromyalgia

Tonix Pharmaceuticals Holding Corp. Announces Data Presentations Involving TNX-1500 (Anti-CD40L mAb) for the Prevention of Rejection in Kidney and Heart Allograft Transplantation in Animal Models At the 2023 American Transplant Congress

Tonix Pharmaceuticals Holding Corp. Announces the Presentation of Data Detailing the Mechanism of Action and Pharmacokinetics of TNX-601 ER

Tonix Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita